v3.25.2
STATEMENTS OF CONDENSED CONSOLIDATED COMPREHENSIVE INCOME (LOSS) (unaudited) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Statement of Comprehensive Income [Abstract]        
Sales - Note P $ 463 $ 544 $ 1,347 $ 1,591
Cost of sales 331 358 957 1,147
Gross profit 132 186 390 444
Selling, general and administrative expense 106 114 268 303
Research and development expense 13 15 41 42
Intangibles amortization expense - Note G 15 19 47 59
Equity and other income 0 0 1 3
Goodwill impairment - Note G 706 0 706 0
Loss on acquisitions and divestitures, net - Note B 0 99 165 100
Operating loss (708) (61) (836) (57)
Net interest and other expense (income) (5) 7 34 (14)
Other net periodic benefit loss - Note K 1 2 4 6
Loss from continuing operations before income taxes (704) (70) (874) (49)
Income tax expense (benefit) - Note J 15 (101) (19) (229)
Income (loss) from continuing operations (719) 31 (855) 180
Loss from discontinued operations, net of income taxes - Note C (23) (25) (22) (27)
Net income (loss) $ (742) $ 6 $ (877) $ 153
Basic earnings (loss) per share - Note M        
Income (loss) from continuing operations $ (15.7) $ 0.61 $ (18.39) $ 3.57
Loss from discontinued operations (0.51) (0.49) (0.46) (0.53)
Net income (loss) (16.21) 0.12 (18.85) 3.04
Diluted earnings (loss) per share - Note M        
Income (loss) from continuing operations [1] (15.7) 0.6 (18.39) 3.53
Loss from discontinued operations (0.51) (0.48) (0.46) (0.52)
Net income (loss) $ (16.21) $ 0.12 $ (18.85) $ 3.01
COMPREHENSIVE INCOME (LOSS)        
Net income (loss) $ (742) $ 6 $ (877) $ 153
Other comprehensive income (loss), net of tax        
Unrealized translation gain (loss) 91 (25) 46 2
Unrealized gain (loss) on commodity hedges (1) 2 2 2
Other comprehensive income (loss) - Note N 90 (23) 48 4
Comprehensive income (loss) $ (652) $ (17) $ (829) $ 157
[1] As a result of the loss from continuing operations attributable to Ashland during the three and nine months ended June 30, 2025, the effect of the share-based awards convertible to common stock would be antidilutive and have been excluded from the diluted EPS calculation.